McNeil recalls some Motrin products from retailers
FDA announced in late December that McNeil Consumer Healthcare Division of McNeil is voluntarily recalling certain lots of Motrin IB 24-count coated caplets, Motrin IB 24-count coated tablets, and Motrin IB 24+6-count coated caplets from retailers.
FDA announced in late December that McNeil Consumer Healthcare Division of McNeil is voluntarily recalling certain lots of Motrin IB 24-count coated caplets, Motrin IB 24-count coated tablets, and Motrin IB 24+6-count coated caplets from retailers.
The company is recalling the products (about 12 million bottles) because testing of product samples showed that some caplets may not dissolve as quickly as intended when nearing their expiration date.
This is not a consumer-level recall, which means that consumers do not need to dispose of or return the product. There is no safety concern if consumers continue taking the product in accordance with its label; however, it is possible there may be a delay in experiencing relief. This action is not being undertaken on the basis of adverse events.
For a complete list of recalled Motrin products, visit the company’s website.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
